Results 111 to 120 of about 35,846 (211)

Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials. [PDF]

Int J Mol Sci
Hung CM, Hsu CW, Zeng BS, Suen MW, Chen JJ, Zeng BY, Carvalho AF, Stubbs B, Chen YW, Chen TY, Hsu SP, Wang HY, Liang CS, Tu YK, Tseng PT.   +14 more
europepmc   +1 more source

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer's Disease Therapy. [PDF]

Biomedicines, 2023
Złotek M, Kurowska A, Herbet M, Piątkowska-Chmiel I.   +3 more
europepmc   +1 more source

Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease. [PDF]

Diabetes Res Clin Pract
Hong AT, Lin F, Luu IY, Shin L, Han SM, Armstrong DG, Tan TW.   +6 more
europepmc   +1 more source

Comparative Efficacy, Safety, and Cost-Utility of DPP-4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real-World Clinical and Economic Outcomes. [PDF]

J Diabetes Res
Jimoh AO, Hudu SA, Sabir AA, Adamu AA, Bello N, Tahir A, Abubakar N.   +6 more
europepmc   +1 more source

Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents. [PDF]

Molecules, 2023
Mathur V, Alam O, Siddiqui N, Jha M, Manaithiya A, Bawa S, Sharma N, Alshehri S, Alam P, Shakeel F.   +9 more
europepmc   +1 more source

NeSyDPP-4: discovering DPP-4 inhibitors for diabetes treatment with a neuro-symbolic AI approach. [PDF]

Front Bioinform
Hossain D, Saghapour E, Chen JY.
europepmc   +1 more source

Molecular Insights into the Potential Cardiometabolic Effects of GLP-1 Receptor Analogs and DPP-4 Inhibitors. [PDF]

Int J Mol Sci
Król M, Kupnicka P, Żychowska J, Kapczuk P, Szućko-Kociuba I, Prajwos E, Chlubek D.   +6 more
europepmc   +1 more source

DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes. [PDF]

Future Virol, 2023
Nag S, Mandal S, Mukherjee O, Mukherjee S, Kundu R.   +4 more
europepmc   +1 more source

Retraction: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

Beyond glycemic control: the cardiac and hepatic benefits of SGLT2 and DPP-4 inhibitors in mitigating chronic cadmium-induced inflammation, oxidative/nitrative stress, apoptosis and fibrosis. [PDF]

Front Physiol
Hassan FE, Hassanien MM, Selmy A, Mahmoud LM, Darwish A, Aldreny BA.   +5 more
europepmc   +1 more source